Europe

Treatment at diagnosis by country

Global enrolment of Prospective patients		
Region	**n**	**%**
Europe	29167	56
Asia	14988	28.8
North America	1618	3.1
Latin America	4247	8.2
Rest of World	2061	4
Total	52081	100



Treatment at diagnosis by country



Treatment at diagnosis by region



Treatment at diagnosis by cohort



Baseline characteristics

		Europe N=(29167)	World N=(52081)
Sex	Female, n (%)	13199 (45.3)	23015 (44.2)
Age at Diagnosis (Years)	mean (sd)	70.8 (10.9)	69.7 (11.5)
Age Group	<65, n (%)	7707 (26.4)	15716 (30.2)
	65-74, n (%)	9543 (32.7)	16956 (32.6)
	>=75, n (%)	11917 (40.9)	19409 (37.3)
BMI (kg/m²)	mean (sd)	28.9 (5.5)	27.8 (5.7)
Pulse (bpm)	mean (sd)	91.0 (27.3)	90.4 (26.7)
Systolic BP (mm Hg)	mean (sd)	136.1 (19.4)	133.5 (19.8)
Diastolic BP (mm Hg)	mean (sd)	80.9 (12.2)	79.7 (12.9)
Congestive heart failure	n (%)	5974 (20.5)	10405 (20.0)
Coronary artery disease	n (%)	6942 (23.8)	11251 (21.6)
Acute coronary syndrome	n (%)	2903 (10.0)	4914 (9.5)
Carotid Occlusive Disease	n (%)	1064 (3.7)	1546 (3.0)
Cirrhosis	n (%)	145 (0.5)	296 (0.6)

Baseline characteristics

		Europe N=(29167)	World N=(52081)
Diabetes	n (%)	6200 (21.3)	11550 (22.2)
History of Bleeding	n (%)	753 (2.6)	1320 (2.5)
Hypercholesterolaemia	n (%)	13155 (46.6)	20975 (41.6)
PE or DVT	n (%)	985 (3.4)	1356 (2.6)
Stroke/TIA	n (%)	3365 (11.5)	5961 (11.4)
Treatment Sector	In the private sector, n (%)	2259 (9.4)	12547 (28.5)
	In the public sector, n (%)	21704 (90.6)	31431 (71.5)

Baseline characteristics

		Europe N=(29167)	World N=(52081)
CHADS2 Score	mean (sd)	1.9 (1.1)	1.9 (1.1)
CHA2DS2-VASc Score	mean (sd)	3.3 (1.5)	3.2 (1.6)
HAS BLED Score	mean (sd)	1.4 (0.9)	1.4 (0.9)

Baseline characteristics

		Europe N=(29167)	World N=(52081)
Systemic Embolization	n (%)	194 (0.7)	336 (0.6)
Type of AF Diagnosed	New, n (%)	13351 (45.8)	23366 (44.9)
	Paroxysmal, n (%)	7173 (24.6)	14313 (27.5)
	Permanent, n (%)	4394 (15.1)	6639 (12.7)
	Persistent, n (%)	4247 (14.6)	7761 (14.9)
Care Setting Speciality at Diagnosis	Cardiology, n (%)	16136 (55.3)	34219 (65.7)
	Geriatrics, n (%)	148 (0.5)	202 (0.4)
	Internal Medicine, n (%)	6283 (21.5)	9372 (18.0)
	Neurology, n (%)	622 (2.1)	876 (1.7)
	Primary Care/General Practice, n (%)	5976 (20.5)	7410 (14.2)

Main reason anticoagulant not used for patients with CHA_2DS_2-VASc >=2 .

	Cohort 1&2	
	Europe (N=2146) n %	World (N=4137) n %
Patients with CHA_2DS_2-VASc >=2 and no AC treatment at diagnosis		
Alcohol abuse	15 (0.7)	20 (0.5)
Already taking anti-platelet drugs for other medical condition	92 (4.3)	228 (5.5)
Patient refusal	223 (10.4)	336 (8.1)
Previous bleeding event	39 (1.8)	63 (1.5)
Taking medication contraindicated or cautioned for use with VKA or AC	10 (0.5)	19 (0.5)
Other	364 (17.0)	505 (12.2)
Unknown	444 (20.7)	889 (21.5)
Physician's choice	959 (44.7)	2077 (50.2)
Physician's choice - Bleeding risk	138 (6.4)	263 (6.4)
Physician's choice - Concern over patient compliance	87 (4.1)	182 (4.4)
Physician's choice - Guideline recommendation	53 (2.5)	105 (2.5)
Physician's choice - Fall risk	160 (7.5)	197 (4.8)
Physician's choice - Low risk of stroke	177 (8.2)	326 (7.9)
Physician's choice - Other	344 (16.0)	1004 (24.3)
Total	2146 (100.0)	4137 (100.0)

Main reason anticoagulant not used for patients with CHA_2DS_2-VASc >=2.

	Cohort 3&4&5	
	Europe (N=2454) n %	World (N=6117) n %
Patients with CHA_2DS_2-VASc >=2 and no AC treatment at diagnosis		
Alcohol abuse	27 (1.1)	32 (0.5)
Already taking anti-platelet drugs for other medical condition	154 (6.3)	422 (6.9)
Patient refusal	325 (13.2)	645 (10.5)
Previous bleeding event	75 (3.1)	151 (2.5)
Taking medication contraindicated or cautioned for use with VKA or AC	38 (1.5)	63 (1.0)
Other	604 (24.6)	1326 (21.7)
Unknown	505 (20.6)	1597 (26.1)
Physician's choice	726 (29.6)	1881 (30.8)
Physician's choice - Bleeding risk	202 (8.2)	611 (10.0)
Physician's choice - Concern over patient compliance	96 (3.9)	248 (4.1)
Physician's choice - Guideline recommendation	87 (3.5)	189 (3.1)
Physician's choice - Fall risk	87 (3.5)	205 (3.4)
Physician's choice - Low risk of stroke	254 (10.4)	628 (10.3)
Total	2454 (100.0)	6117 (100.0)

Stroke risk profile: CHADS2



Stroke risk profile: CHA2DS2 VASc



Stroke risk profile: HAS BLED



Treatment at diagnosis by CHA2DS2-VASc score - Europe

	CHA2DS2-VASc	VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total
		n	n	n	n	n	n	n
Europe	Unknown	308	122	39	133	172	7	781
	0	134	88	42	81	122	9	476
	1	1022	508	275	589	489	49	2932
	2	2379	1060	479	942	549	78	5487
	3	3224	1509	485	1165	618	99	7100
	4	3136	1316	503	1032	505	94	6586
	5	1625	675	242	638	222	56	3458
	6-9	1070	495	141	468	125	48	2347

Treatment at diagnosis by CHA2DS2-VASc score - World

	CHA2DS2-VASc	VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total
		n	n	n	n	n	n	n
World	Unknown	461	227	62	286	330	14	1380
	0	325	221	111	302	443	16	1418
	1	1830	1097	479	1545	1196	66	6213
	2	3835	1960	806	2154	1261	125	10141
	3	4969	2625	817	2345	1275	164	12195
	4	4711	2352	772	2043	1028	168	11074
	5	2458	1169	375	1224	449	98	5773
	6-9	1616	831	234	872	261	73	3887

Treatment at diagnosis



	0	1	2	3	4	5	6-9	All
VKA±AP	28.7	35.4	44	46.1	48.3	47.8	46.5	44.9
FXa±AP	18.8	17.6	19.6	21.6	20.3	19.8	21.5	20.1
DTI±AP	9	9.5	8.9	6.9	7.7	7.1	6.1	7.7
AP	17.3	20.4	17.4	16.6	15.9	18.8	20.4	17.6
None	26.1	17	10.1	8.8	7.8	6.5	5.4	9.8

CHA2DS2-VASc score - Europe

Treatment at diagnosis



	0	1	2	3	4	5	6-9	All
VKA±AP	23.2	29.8	38.3	41.3	43.2	43.3	42.4	39.3
FXa±AP	15.8	17.8	19.6	21.8	21.6	20.6	21.8	20.4
DTI±AP	7.9	7.8	8	6.8	7.1	6.6	6.1	7.1
AP	21.5	25.1	21.5	19.5	18.7	21.6	22.9	21
None	31.6	19.5	12.6	10.6	9.4	7.9	6.8	12.2

CHA2DS2-VASc score - World

Treatment at diagnosis by HAS BLED score - Europe

HASBLED		VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total	
		n	n	n	n	n	n	N	n
Europe	Unknown	3683	1537	556	1574	1019	93	8462	8462
	0	1245	597	344	0	526	64	2776	2776
	1	4374	2010	762	1009	751	152	9058	9058
	2	2666	1226	411	1673	367	93	6436	6436
	3	781	350	123	659	120	32	2065	2065
	4-9	149	53	10	133	19	6	370	370

Treatment at diagnosis by HAS BLED score - World

	HASBLED	VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total
		n	n	n	n	n	n	n
World	Unknown	5750	2456	843	3271	2060	147	14527
	0	2144	1242	611	0	1394	96	5487
	1	6650	3866	1303	2302	1779	254	16154
	2	4165	2225	689	3689	763	163	11694
	3	1258	599	191	1250	219	53	3570
	4-9	238	94	19	259	28	11	649

Treatment at diagnosis



Treatment at diagnosis



INR values and time in therapeutic range

Variable	Statistics	Europe (N = 12898) n %	World (N = 20205) n %
INR value, n(%)	n (missing)	120625 (4941)	157134 (8319)
	<2	32894 (27.3)	50514 (32.1)
	2-3	66842 (55.4)	81056 (51.6)
	>3	20889 (17.3)	25564 (16.3)
INR value	n (missing)	120625 (4941)	157134 (8319)
	Mean (SD)	2.4 (0.9)	2.4 (0.9)
	Median (IQR)	2.3 (1.9 to 2.8)	2.3 (1.8 to 2.8)
	Min to Max	0.8 to 20.0	0.8 to 20.0
TTR, n(%)	n (missing)	7799 (5099)	11485 (8720)
	<65	3924 (50.3)	6734 (58.6)
	>=65	3875 (49.7)	4751 (41.4)
TTR	n (missing)	7799 (5099)	11485 (8720)
	Mean (SD)	61.8 (23.9)	55.2 (27.3)
	Median (IQR)	64.8 (47.2 to 79.4)	59.0 (37.0 to 76.1)
	Min to Max	0.0 to 100.0	0.0 to 100.0

Event rates during the first year of follow-up (rates per 100 person-years)

	Europe		World	
	Events	**Rate (95% CI)**	**Events**	**Rate (95% CI)**
Death	1242	4.53 (4.28 to 4.79)	2103	4.38 (4.20 to 4.57)
Cardiovascular Death	468	1.71 (1.56 to 1.87)	789	1.64 (1.53 to 1.76)
Non-cardiovascular death	465	1.69 (1.55 to 1.86)	771	1.61 (1.50 to 1.72)
Undetermined Cause	309	1.13 (1.01 to 1.26)	543	1.13 (1.04 to 1.23)
Stroke/SE	369	1.35 (1.22 to 1.50)	650	1.36 (1.26 to 1.47)
Major Bleeding	262	0.96 (0.85 to 1.08)	407	0.85 (0.77 to 0.94)
Acute coronary syndrome	251	0.92 (0.81 to 1.04)	378	0.79 (0.71 to 0.87)
Congestive hearth failure	684	2.53 (2.35 to 2.73)	1052	2.22 (2.09 to 2.35)

Cause of death during the first year of follow-up

	Europe		World	
	n	%	n	%
Cardiovascular causes				
Congestive heart failure	149	31.8	262	33.2
Sudden or unwitnessed death	75	16.0	127	16.1
Myocardial infarction	48	10.3	89	11.3
Non-haemorrhagic stroke (Ischemic Stroke)	50	10.7	86	10.9
Non Cardiovascular causes				
Malignancy	157	33.8	233	30.2
Respiratory failure	82	17.6	142	18.4
Infection	45	9.7	81	10.5
Sepsis	38	8.2	74	9.6

Type of stroke during the first year of follow-up

	Europe		World	
	n	%	n	%
Stroke (not including systemic embolism)	323	1.11	585	1.12
Primary Ischemic	228	0.78	406	0.78
of which secondary hemorrhagic ischemic	7	0.02	22	0.04
Primary intracerebral hemorrhage	41	0.14	71	0.14
Intracerebral	27	0.09	44	0.08
Intraventricular	5	0.02	9	0.02
Subarachnoid	6	0.02	13	0.02
Undetermined	54	0.19	108	0.21

Severity of bleeding during the first year of follow-up

Oucome	Europe		World	
	n	%	n	%
Major Bleed	262	0.50	407	0.78
Non-Major Clinically Relevant	456	0.88	645	1.24
Minor	778	1.49	1167	2.24
Unknown	78	0.15	136	0.26